Our Company

The RNAscope in situ hybridization (ISH) assay provides spatial visualization of biodistribution and efficacy of AAV vector-mediated gene delivery. Low transduction efficiency, off-target tropism and overcoming pre-existing immunogenicity are some of the challenges presented when developing AAV based gene therapeutics. Capsid engineering can improve transduction efficiency, cellular and tissue tropism, and overcome immunogenicity. Therefore, selection of engineered capsids that demonstrate desirable properties is critical to making informed decisions for AAV-based gene therapies. The RNAscope in situ hybridization assay guides the selection of the optimal capsid demonstrating improved and selective transduction of the viral vector to safely deliver cargo intracellularly, improving tissue tropism with functional efficiency as well as persistence over time.

You will also learn about our flexible, scalable multi-omic service offerings with expert end-to-end RNAscope Professional Assay Services (PAS) including early access to new assay capabilities.